Home Apoptosis OXPHOS

OXPHOS

Other Apoptosis Related Inhibitors

Caspase Bcl-2 p53 Ferroptosis PD-1/PD-L1 Survivin TNF-alpha MDM2/MDMX KRas IAP
Cat.No. Product Name Information Product Use Citations Product Validations
S8731 IACS-010759 (IACS-10759) IACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I.
Cell, 2025, S0092-8674(25)01233-4
Cell Rep, 2025, 44(7):115901
Cell Commun Signal, 2025, 23(1):47
S9736 ME-344 ME-344 is a synthetic metabolite of NV-128, a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, disrupting ATP generation and oxygen consumption. It also inhibits mTOR by downregulating the AKT/mTOR pathway, exhibiting anticancer activity by inhibiting cell growth and viability in leukemia cell lines with IC50 values of 70–260 nM.
S8276 FCCP FCCP (Trifluoromethoxy carbonylcyanide phenylhydrazone, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes.
Nature, 2025, 10.1038/s41586-024-08395-9
Nat Commun, 2025, 16(1):3012
Cell Death Dis, 2025, 16(1):163
Verified customer review of FCCP
S8828 Gboxin Gboxin is an inhibitor of oxidative phosphorylation in cancer cells. This compound inhibits the activity of F0F1 ATP synthase. It specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes.
Cell Rep, 2025, 44(7):115901
Cell Rep, 2024, 43(10):114775
Mol Oncol, 2023, 17(9):1821-1843
S0096 S-Gboxin S-Gboxin, a functional analogue of Gboxin, is an oxidative phosphorylation (OXPHOS) inhibitor which inhibits growth of mouse and human glioblastoma (GBM) with IC50 of 470 nM.
STAR Protoc, 2025, 6(2):103719
Cell Rep Med, 2024, 5(10):101757
EMBO Mol Med, 2022, 14(12):e16082
S2987 4-Methyl-2-oxovaleric acid 4-Methyl-2-oxovaleric acid (Ketoleucine, 4-MOV, KIC, 4-Methyl-2-oxopentanoic acid, alpha-Ketoisocaproic acid, alpha-ketoisocaproate, 2-Oxoisohexanoate) is released by Astrocytes to neurons and can be reaminated by aminotransferase to leucine. 4-Methyl-2-oxovaleric acid reduces the rate of protein degradation in skeletal muscle. 4-Methyl-2-oxovaleric acid acts as an uncoupler of oxidative phosphorylation (OXPHOS) and as a metabolic inhibitor possibly through its inhibitory effect on alpha-ketoglutarate dehydrogenase (oxoglutarate dehydrogenase complex, OGDC) activity.
Nature, 2024, 10.1038/s41586-024-08307-x
S8943 VLX600 VLX600 is a novel iron-chelating inhibitor of oxidative phosphorylation (OXPHOS), potentiates the effect of radiation in tumor spheroids in a synergistic manner. This compound shows enhanced cytotoxic activity under conditions of nutrient starvation. It induces autophagy and mitochondrial inhibition with antitumor activity.
Cancers (Basel), 2022, 14(13)3225
E4709 MS-L6 MS-L6(Agn-PC-0N3ahi, NSC34338) is a potent inhibitor of OXPHOS, targeting electron transport chain complexes I (ETC-I), combining inhibition of NADH oxidation and uncoupling effect, on the respiratory chain. It exhibits potent antitumor efficacy.
E5927New Mito-LND (Mito-Lonidamine) Mito-LND (Mito-Lonidamine) is a mitochondria-targeted derivative of lonidamine conjugated with a triphenylphosphonium cation that selectively accumulates in cancer cell mitochondria due to their high membrane potential. It potently inhibits oxidative phosphorylation (OXPHOS) by disrupting respiratory complexes I and II, stimulating ROS production and Prx3 oxidation while suppressing AKT/mTOR/p70S6K signaling.
E1139 DX3-213B DX3-213B is a highly potent, orally active oxidative phosphorylation (OXPHOS) complex I inhibitor with IC50 of 3.6 nM, and impairs ATP generation with IC50 of 11 nM.